Belite Bio (BLTE) reported a Q4 net loss Monday of $0.32 per diluted share, widening from a loss of $0.25 a year earlier.
Analysts polled by FactSet expected a loss of $0.31.
As of the end of 2024, the company said it had a cash balance of $31.7 million.